Genetics & Personalised Medicine - Whole genome association and genetic linkage studies By Dr John W. Hooper Genetic linkage studies have long been the standard for researching the genetics associated with heritable diseases. Recently, however, scientists have begun to realise the benefits of whole genome association studies, which enable them… Read More
The Role of Microarray Technology in Pharmaceutical Development and Diagnostics By Richard Fisler The expectation that microarray technology will play a large role in shaping the future of pharmaceutical development and diagnostics has greatly increased due to new products and applications. Microarrays for gene expression have made a profound impact… Read More
Emerging concepts of G protein-coupled receptor (GPCR) function and drug discovery By Dr Richard M. Eglen, Dr Roger Bosse and Dr Graham S. Long G protein-coupled cell surface receptors (GPCRs) have served a fundamental role in modern pharmacology, due to their central importance in cell communication, and have been the… Read More
The Role of Repositioning in Drug Discovery and Development By Dr Louis A. Tartaglia and Dr Lee E. Babiss The large number of drug candidate failures in recent years has been enormously costly for the pharmaceutical industry, but has also created the tremendous opportunity of repositioning these molecules into new… Read More
The Genome as a Tool for Drug Discovery and Development the Case for Embracing Complexity By Dr Kenneth C. Carter Conventional drug discovery and development is centred on a paradigm in which 'validated' targets are subjected to in vitro screens for the identification of new drug candidates. Molecular profiling using… Read More
Kinase Inhibitor Screening - Latest technologies and techniques By Dr Richard M. Eglen and Dr Roger Bossé Kinases have become a proven target class for new drugs and have created a thirst for the development of new technology platforms for inhibitor detection. We discuss some of the latest technologies and… Read More
Confocal vs Widefield High Content Imaging By Dr John Comley A variety of new confocal hardware and software solutions have recently become available to support high content imaging. Most of the solutions have in common the potential of rejecting out-of-focus background fluorescence and of improving the signal to noise of… Read More
The Biomedical Ecosystem Delivering Better Health and Prosperity By Dr Peter B. Corr The overall message is simple: biomedical innovation and the public policies and new technologies that sustain and advance innovation are crucial to the future of biomedical science and the health and well being of our society. In… Read More
Ion Channel Drug Targets: Unlocking the potential By Dr Dayle S. Hogg, Dr Philip Boden, Dr Geoff Lawton and Dr Roland Z. Kozlowski A striking number of drugs targeting ion channels have reached blockbuster status, generating $ billion revenues. In spite of the historical success of ion channels as therapeutic… Read More
Miniaturisation of Assay Development and Screening By Andreas Boettcher and Dr Lorenz M. Mayr In recent years we have seen a strong increase in the number of chemical compounds and molecular targets used for lead discovery by high-throughput screening among most Pharma and Biotech companies. This has caused a strong… Read More
Current Biosensor Technologies in Drug Discovery By Dr Matthew A. Cooper Over the past two decades the benefits of biosensor analysis have begun to make an impact in the market, and systems are beginning to be used as mainstream research tools in many laboratories. Biosensors are devices that use biological… Read More
Changing Dynamics in Dispense and Imaging Assays By Dr John Comley The prospects for a significant shift in dispense and imaging (D&I) assays towards a greater utilisation of calcium-mediated flash luminescence readouts appears to be finally under way. Driving this changing dynamic is the acceptance that assay sensitivity (better quality… Read More
The Timetable of Invention and it's Relevance to Drug Discovery By Dr William Bains The most critical question to any investor in new technology should not be whether a technology will work. Technologies nearly always work in the end, providing they do not break fundamental laws of physics, and are… Read More
By Dr Alpheus Bingham It has been suggested that the blockbuster business model, which has been the key to big pharma success, is now broken and completely beyond repair. In a truly global and fast changing business world, is it time to examine alternatives to the classic monolithic risk structure… Read More
By Dr George G. Harrigan The potential of metabolomics, a systems approach to biochemical pathway analysis, to yield scientific and commercial benefits to healthcare and biotechnology enterprises is increasingly recognised. This article discusses current applications and future developments and places an emphasis on incorporation of metabolomics within all aspects of… Read More
High Throughput Screening: meeting the challenges of more cell-based assays and HCS By Sandra Fox, MBA The use of high content screening and cell-based assays within high throughput screening (HTS) laboratories is on the increase but there are still many challenges to overcome. Each year, HTS laboratories perform slightly more… Read More